Adenocarcinoma
|
0.700 |
GeneticVariation
|
group |
CLINVAR |
|
|
|
Adenocarcinoma
|
0.700 |
AlteredExpression
|
group |
BEFREE |
<b>Results:</b> p16 and p53 were detected in 50.7 and 57.3% of adenocarcinoma (ADCs; n = 75), and 35.2 and 63.6% of squamous cell carcinoma (n = 88).
|
31157548 |
2019 |
Adenocarcinoma
|
0.700 |
GeneticVariation
|
group |
BEFREE |
20 of the 32 (69%) NSCLC patients contained mutant P53 in the yeast functional assay with the higher frequency in squamous cell carcinoma (14/17, 82%) than in adenocarcinoma (5/10, 50%) and large cell carcinoma (3/5, 60%) (p<0.01, chi2 test).
|
11374799 |
2001 |
Adenocarcinoma
|
0.700 |
GeneticVariation
|
group |
BEFREE |
46/103 (44.6%) NSCLC showed p53 mutations and 17/103 (16.5%) c-Ki-ras mutations including 12/37 (32.4%) adenocarcinomas.
|
10945494 |
2000 |
Adenocarcinoma
|
0.700 |
Biomarker
|
group |
BEFREE |
Adenocarcinoma arising in Barrett's oesophagus: evidence for the participation of p53 dysfunction in the dysplasia/carcinoma sequence.
|
8020801 |
1994 |
Adenocarcinoma
|
0.700 |
GeneticVariation
|
group |
BEFREE |
TP53 mutations were found in 47 of 94 primary tumors (50%), and K-ras mutations were present in 26 of 55 adenocarcinomas (47%).
|
11882817 |
2002 |
Adenocarcinoma
|
0.700 |
AlteredExpression
|
group |
LHGDN |
TP53 and SMAD4 status were determined by immunohistochemistry on tissue microarrays of 23 archival familial pancreatic adenocarcinomas and in selected cases by cycle sequencing to identify TP53 gene mutations.
|
19064568 |
2008 |
Adenocarcinoma
|
0.700 |
GeneticVariation
|
group |
BEFREE |
TP53 mutation positive status was most common in adenocarcinoma (OR 2.0, 95% CI, 1.1-3.7; compared with squamous cell carcinoma), and mutation positivity showed an overall, nonsignificant association with wood-dust exposure (OR 1.6, 95% CI, 0.8-3.1).
|
19950227 |
2010 |
Adenocarcinoma
|
0.700 |
GeneticVariation
|
group |
BEFREE |
TP53 mutations were detected in 48.8% of cases and were more frequent among SCCs than ADCs (p<0.0001).
|
22267755 |
2012 |
Adenocarcinoma
|
0.700 |
GeneticVariation
|
group |
BEFREE |
TP53 mutations were identified in 9.1% of intermediate-grade IPMNs (2 of 22), 17.8% of PanIN-2 (8 of 45), 38.1% of high-grade IPMNs (8 of 21), 47.6% of PanIN-3 (10 of 21), and 75% of invasive pancreatic adenocarcinomas (15 of 20); no TP53 mutations were found in PanIN-1 lesions or low-grade IPMNs.
|
23200980 |
2013 |
Adenocarcinoma
|
0.700 |
GeneticVariation
|
group |
BEFREE |
TP53 mutations were observed exclusively in four adenocarcinoma components, consistent with their role in the progression from adenoma to adenocarcinoma.
|
24470207 |
2014 |
Adenocarcinoma
|
0.700 |
AlteredExpression
|
group |
BEFREE |
A case of pulmonary adenocarcinoma with overexpression of multidrug resistance-associated protein and p53 aberration.
|
10928127 |
2000 |
Adenocarcinoma
|
0.700 |
Biomarker
|
group |
CTD_mouse |
A mouse model for tumor progression of lung cancer in ras and p53 transgenic mice.
|
16247444 |
2006 |
Adenocarcinoma
|
0.700 |
GeneticVariation
|
group |
BEFREE |
A total of 297 resected Japanese non-small cell lung cancers (74 squamous cell carcinomas and 223 adenocarcinomas) were analyzed to evaluate the validity of the p53 mutation spectrum as a fingerprint for mutagenic substances as etiological factors.
|
18271927 |
2008 |
Adenocarcinoma
|
0.700 |
Biomarker
|
group |
BEFREE |
Aberrant p53 protein accumulation was measured immunohistologically in 342 colorectal paraffin-embedded tissue sections from 115 patients (24 with adenocarcinoma, 59 with adenoma and 32 'hospital controls').
|
12944180 |
2004 |
Adenocarcinoma
|
0.700 |
AlteredExpression
|
group |
BEFREE |
Aberrant methylations of p16INK4a and p14ARF gene were present in 21 (32.3%) and 33 (50.8%) out of 65 cases, respectively. p16INK4a aberrant methylation was correlated with p16 negativity (P=0.021) and p53 overexpression (P=0.007). p16INK4a aberrant methylation was more frequently present in poorly differentiated adenocarcinomas (P=0.002).
|
16675157 |
2006 |
Adenocarcinoma
|
0.700 |
GeneticVariation
|
group |
BEFREE |
Abnormalities involving the p16 (also known as cyclin-dependent kinase N2 [CDKN2], p16 [INK4a], or MTS1) and p53 (also known as TP53) tumor suppressor genes are highly prevalent in esophageal adenocarcinomas.
|
10601379 |
1999 |
Adenocarcinoma
|
0.700 |
AlteredExpression
|
group |
BEFREE |
Abnormalities of the tumour suppressor gene p53 have been shown in approximately 60% of advanced gastric adenocarcinomas and it has been suggested that the immunohistochemical finding of increased p53 expression is a prognostic marker in gastric cancer.
|
7829004 |
1994 |
Adenocarcinoma
|
0.700 |
GeneticVariation
|
group |
BEFREE |
According to the analysis, typical EBV-associated gastric adenocarcinoma constitutes an independent molecular pathological subgroup, which is mutually exclusive to TP53-mutated adenocarcinoma with chromosomal instability, another molecular pathological subtype in gastric adenocarcinomas.
|
26617924 |
2015 |
Adenocarcinoma
|
0.700 |
GeneticVariation
|
group |
BEFREE |
Age-associated increase of codon 72 Arginine p53 frequency in gastric cardia and non-cardia adenocarcinoma.
|
12796380 |
2003 |
Adenocarcinoma
|
0.700 |
AlteredExpression
|
group |
BEFREE |
Allelic imbalances in D3S1283, D3S1234, D3S1300, D3S1285, TP53, D17S938, and D9S179 were less frequent in SH than in adenocarcinoma; rates of allelic imbalances in D20S170 and D21S1446 were not significantly different.
|
21649526 |
2011 |
Adenocarcinoma
|
0.700 |
Biomarker
|
group |
BEFREE |
Alterations in tumor suppressor genes, amongst which p53 and p16, are early events in the metaplasia-dysplasia-adenocarcinoma sequence, followed by loss of cell cycle checkpoints.
|
16299787 |
2005 |
Adenocarcinoma
|
0.700 |
AlteredExpression
|
group |
BEFREE |
Alterations of APC, KRAS and TP53 were observed in a higher percentage of adenocarcinomas compared to adenomas (P<0.05) indicating that the alterations accumulated with malignancy.
|
19576232 |
2009 |
Adenocarcinoma
|
0.700 |
AlteredExpression
|
group |
BEFREE |
Alterations of the retinoblastoma (Rb) gene were evaluated in nine primary endometrial adenocarcinomas that we had previously analyzed for the presence of Ki-ras activations and p53 alterations and in three endometrial carcinoma cell lines.
|
8105795 |
1993 |
Adenocarcinoma
|
0.700 |
AlteredExpression
|
group |
BEFREE |
Altered immunohistochemical detection of c-erbB-2, DF3, B72.3, p53 and Ki-67 was observed with progression and differentiation to two distinct histologic types of invasive carcinoma. c-erbB-2 and DF3 were detected in 50% and 18% of lesions at the stage of atypical hyperplasia and expression increased to 78% and 54% in invasive adenocarcinomas.
|
9458364 |
1998 |